BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin
June 20, 2016 at 12:50 PM EDT
* Phase 2 study of Relebactam, in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint